PreVenTB Trial Proves Efficacy of Indigenous TB Vaccines

The Indian Council of Medical Research successfully concluded the PreVenTB Phase III clinical trial, demonstrating that indigenous vaccines VPM1002 and Immuvac provide critical protection against extrapulmonary tuberculosis. The trial highlighted significant efficacy among high-risk household contacts and children, offering a highly scalable and cost-effective biomedical tool for India’s ambitious TB elimination targets.